ArticleBMC infectious diseases2025
Genotyping and refractory risk factors of mycoplasma pneumoniae pneumonia in Suzhou, China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- MiR-128-3p serves as a diagnostic biomarker in pediatric Mycoplasma pneumoniae pneumonia.BMC pulmonary medicine · 2026Article
- Mapping the Evolution of Diagnostic Research onPathogens (Basel, Switzerland) · 2026Review
- Qingxuan Zhike Granules Modulate Gut Dysbiosis and Enhance Intestinal Repair in MurineJournal of microbiology and biotechnology · 2026Article
- Obstructive fibrinous tracheal pseudomembrane complicated with bronchial mucus plug: A rare post-intubation complication case report.Journal of anesthesia and translational medicine · 2026Article
- Article
- Macrolide-resistantFrontiers in pediatrics · 2026Article
- The impact of the COVID-19 pandemic on the epidemiology, clinical manifestations and molecular characteristics ofFrontiers in immunology · 2026Review
- Age and hypoalbuminemia independently predict pulmonary consolidation in children with 23S rRNA A2063G-mutantFrontiers in pediatrics · 2026Article
- Highly sensitive PfAgo-based biosensor for the detection of mutations in the 23S rRNA gene of macrolide-resistant Mycoplasma pneumoniae.Analytical and bioanalytical chemistry · 2025Article
- Immune activation and mucin dysregulation in pediatric refractoryFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo investigate the genotyping and drug resistance of Mycoplasma pneumoniae (MP) epidemic strains in children and analyze the risk factors for refractory Mycoplasma pneumoniae pneumonia (RMPP).
methodNasopharyngeal aspirates (NPA) were collected from hospitalized children with MP infection from September to October 2023. Tracheoscopy was performed when necessary, and Bronchoalveolar Lavage Fluid (BALF) was collected. Polymerase Chain Reaction (PCR) capillary electrophoresis were used to detect respiratory pathogens, and a nested PCR based on the MP P1 gene monitored MP subtypes. The MP-23 S rRNA V region was amplified and sequenced. Clinical data and laboratory results were analyzed for RMPP risk factors.
resultFrom 261 children diagnosed with Mycoplasma pneumoniae pneumonia (MPP), cough (100%) and fever (93.1%) were the most common symptoms. Moist rales (65.5%) were the prevalent pulmonary signs. Bronchoscopy was required in 44.4% of cases. Drug resistance genes were detected in 258 cases (98.9%). Genotyping showed 192 cases (73.56%) as type I and 69 cases (26.4%) as type II. Type I required more bronchoscope interventions (54.2%) compared to type II (17.4%, P < 0.001). Among the children, 92 (35.2%) were classified as RMPP. The RMPP group had longer hospitalization (9.14 ± 4.38 vs. 6.7 ± 1.81 days), higher fever ratio (100% vs. 89.9%), and longer febrile duration (8.72 ± 2.52 vs. 4.56 ± 2.50 days) (all P < 0.05). Higher rates of shortness of breath (7.6% vs. 1.2%) and decreased breath sounds (30.4% vs. 16.6%) were noted in the RMPP group (P < 0.05). Additionally, higher proportions of elevated CRP, ALT, AST, LDH, and D-D dimer were found in the RMPP group, along with a greater need for bronchoscopy (70.7% vs. 43.2%). Multivariate logistic regression identified total febrile duration, mucus plug formation, elevated AST, LDH, and D-D dimer as RMPP risk factors. Receiver operator characteristic (ROC) curve indicated that total febrile duration, LDH, and D-D dimer could serve as predictive markers for RMPP.
conclusionType I predominated among MP strains in Suzhou, with a high prevalence of drug resistance. Type I infections were associated with a higher likelihood of requiring bronchoscopy. Prolonged fever, mucus plug formation, elevated AST, LDH, and D-D dimer were independent risk factors for RMPP, with total febrile duration, LDH, and D-D dimer serving as predictive markers. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.